These results indicate that NY-ESO-1-specific CD4+ T cell precursors present in healthy individuals are susceptible to suppression by regulatory T cells, but in cancer patients, in vivo-primed NY-ESO-1-specific CD4+ T cells become resistant to this suppression [36], [37]. This evidence concerns the gene CD4 and cancer.